\begin{tabular*}{\textwidth}{@{\extracolsep\fill}clllllllllll@{\extracolsep\fill}}
\toprule
&  & \multicolumn{3}{c}{Final Selection (\%)$^1$} & \multicolumn{3}{c}{Allocations (\%)} & &  &  &  \\
\multirow{2}{2em}{Alpha} & \multirow{2}{2em}{Method} & \multirow{2}{2em}{MTD} & \multirow{2}{2em}{Above MTD} & \multirow{2}{2em}{Below MTD} & \multirow{2}{2em}{MTD} & \multirow{2}{2em}{Above MTD} & \multirow{2}{2em}{Below MTD} & \multirow{2}{2em}{Toxic~\%$^2$} & \multirow{2}{2em}{DLTs} & \multirow{2}{2em}{Trial Size} & \multirow{2}{2em}{Days}  \\ \\ 
\midrule
\multirow{4}{2em}{0} & CRM & 49 & 22 & 29 & 29 & 27 & 44 & 27 & 7.3 & 27.7 & 398\\
 & AIDE-CRM & 54 & 20 & 26 & 32 & 28 & 40 & 28 & 9.0 & 27.7 & 399\\
 & $\alpha$-CRM & 54 & 26 & 20 & 32 & 31 & 37 & 31 & 9.3 & 27.8 & 402\\
 & IPDE-POCRM & 55 & 28 & 17 & 32 & 33 & 35 & 33 & 9.7 & 27.8 & 401\\
\midrule
\multirow{4}{2em}{0.3} & CRM & 49 & 22 & 29 & 29 & 27 & 44 & 27 & 7.3 & 27.7 & 398\\
 & AIDE-CRM & 53 & 16 & 30 & 32 & 25 & 43 & 31 & 9.1 & 27.7 & 401\\
 & $\alpha$-CRM & 55 & 22 & 23 & 33 & 29 & 39 & 34 & 9.6 & 27.8 & 400\\
 & IPDE-POCRM & 55 & 24 & 21 & 33 & 31 & 37 & 37 & 10.0 & 27.8 & 399\\
\midrule
\multirow{4}{2em}{0.6} & CRM & 50 & 21 & 29 & 29 & 27 & 44 & 27 & 7.3 & 27.6 & 397\\
 & AIDE-CRM & 50 & 14 & 36 & 30 & 24 & 45 & 31 & 9.3 & 27.8 & 400\\
 & $\alpha$-CRM & 54 & 20 & 26 & 32 & 27 & 40 & 34 & 9.8 & 27.9 & 401\\
 & IPDE-POCRM & 55 & 21 & 24 & 33 & 29 & 38 & 36 & 10.2 & 27.8 & 401\\
\midrule
\multirow{4}{2em}{0.9} & CRM & 49 & 22 & 29 & 29 & 27 & 44 & 27 & 7.3 & 27.7 & 399\\
 & AIDE-CRM & 46 & 12 & 42 & 29 & 22 & 49 & 32 & 9.4 & 27.8 & 400\\
 & $\alpha$-CRM & 53 & 17 & 30 & 31 & 25 & 43 & 35 & 10.0 & 27.8 & 400\\
 & IPDE-POCRM & 54 & 17 & 29 & 32 & 27 & 41 & 37 & 10.5 & 27.7 & 400\\
\bottomrule
\end{tabular*}
